Does continuous cefotaxime administration improve time to attainment and maintenance of target drug levels in intensive care patients?

Does continuous cefotaxime administration improve time to attainment and maintenance of target drug levels in intensive care patients? - Cefotaxime target attainment

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON41771

Enrollment

Registered

2015-06-12

Start date

2015-12-10

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bacterial pneumonia selective decontamination of the digestive tract

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Adult (>= 18 yrs. of age) patients - Admitted to intensive care - Indication for treatment with cefotaxime (as judged by treating physician)

Exclusion criteria

Exclusion criteria: Renal replacement therapy Contraindications for cefotaxime use No indication for an arterial line

Design outcomes

Primary

Measure	Time frame
Total bound and unbound plasma concentrations of cefotaxime; target attainment and maintenance at different time intervals based on a predefined target minimal inhibitory concentration (MIC)	—

Secondary

Measure	Time frame
Describing cefotaxime PK parameters Parameters relevant to pharmacokinetic profile of subjects; including ideal body weight (kgs), actual body weight (kgs), fluid balance (L), creatinine (mg/mL), creatinine clearance (mL/min), derived from creatinine concentration in plasma and a 24-hour aliquot of urine, volume of distribution (total drug dose (mgs) divided by plasma cefotaxime concentration (mg/L)), albumin (mg/mL). To identify relationships between patient characteristics (e.g. APACHE II score, serum albumin concentration, kidney function etc.) and cefotaxime levels that can contribute to optimized dosing in selected patientgroups using multiple regression.	—

Measure

Time frame

Describing cefotaxime PK parameters Parameters relevant to pharmacokinetic profile of subjects; including ideal body weight (kgs), actual body weight (kgs), fluid balance (L), creatinine (mg/mL), creatinine clearance (mL/min), derived from creatinine concentration in plasma and a 24-hour aliquot of urine, volume of distribution (total drug dose (mgs) divided by plasma cefotaxime concentration (mg/L)), albumin (mg/mL). To identify relationships between patient characteristics (e.g. APACHE II score, serum albumin concentration, kidney function etc.) and cefotaxime levels that can contribute to optimized dosing in selected patientgroups using multiple regression.

—

Countries

Netherlands

Outcome results